Lupin Kicks Off 2024 With Major US Generics Launches

Introduces Rival To Prolensa With 180-Day Exclusivity And Challenges Chantix

Lupin has begun 2024 by notching up multiple US approvals and launches, including introducing an exclusive generic version of Prolensa and challenging Chantix.

Shutterstock
Lupin has burst into 2024 with multiple approvals and launches

Lupin has kicked off the new year with multiple US launches and approvals, chief among them its introduction of the first generic rival to Bausch + Lomb’s Prolensa (bromfenac) 0.07% ophthalmic solution, for which the Indian firm will enjoy 180-day first-to-file exclusivity.

Towards the end of November 2023, Lupin received approval for its generic from the US Food and Drug Administration (see...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

FTC’s Latest Effort To Dispute Improper Patent Listings Barely Made A Dent

 

Trump’s FTC has carried on two legacies – trying to eliminate improper drug patent listings and making minimal impact on such efforts.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By 

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

More from Products

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By 

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By 

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.